Finding 50% effective dose of remimazolam for facilitating I-gel insertion with remifentanil target-controlled infusio

Not Applicable

Completed

• Conditions: Not Applicable

• Registration Number: KCT0007801
• Lead Sponsor: Ajou University Hospital

Brief Summary

The remimazolam bolus dose for successful I-gel insertion in 50% of adult patients with Ce 3.0 ng/mL of remifentanil and without NMBAs was 0.280 ± 0.048 mg/kg. From the isotonic regression analysis, ED50 and ED95 were 0.244 (83% CI 0.213–0.313) mg/kg and 0.444 (95% CI 0.436–0.448) mg/kg, respectively.

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-11-02
• Results First Posted: 2023-03-16
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Adult patients aged 19-65 years with ASA score 1 or 2 scheduled for general anesthesia and eligible for I-gel use

Exclusion Criteria

BMI > 30 kg/m2
Patient refusal
Anticipated difficult airway
Anticipated difficult mask ventilation
COPD, astham, pneumonia, active URI
Risk of aspiration
Patients unable to response on verbal command
History of allergies to benzodiazepines
History of allergies to opioids
History of substance abuse/addiction
Pregnant or breastfeeding patients

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dose of remimazolam associated with 50% probability for adequate depth of anesthesia for I-gel insertion with remifentanil target controlled infusion

Secondary Outcome Measures

Name	Time	Method
vital signs (Mean arterial pressure, heartrate, oxygen saturation), Bispectral index(BIS), loss of consciousness time, I-gel insertion time